Jinesh Mehta
Distinguished in Lung Metastases

Dr. Jinesh Mehta

Pulmonary Medicine | Intensive Care Medicine
2950 Cleveland Clinic Boulevard, 
Weston, FL 
On Staff At
Offers Telehealth
Distinguished in Lung Metastases
2950 Cleveland Clinic Boulevard, 
Weston, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jinesh Mehta is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Weston, Florida. Dr. Mehta is rated as a Distinguished provider by MediFind in the treatment of Lung Metastases. His top areas of expertise are Pulmonary Hypertension, Interstitial Lung Disease, Acute Interstitial Pneumonia, Emphysema, and Advanced Bronchoscopy.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Harlem Hospital Center
Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Internal Medicine in FL
Board Certifications
American Board Of Internal Medicine, 2008
Fellowships
University of Louisville School of Medicine
Hospital Affiliations
Cleveland Clinic Hospital
Languages Spoken
English
Gujarati 
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 30 Less Insurance Carriers -

Locations

Egil and Pauline Braathen Center/Maroone Cancer Center
2950 Cleveland Clinic Boulevard, Weston, FL 33331

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

18 Total Publications

BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
Journal: Respiratory medicine
Published: June 18, 2025
Similar Doctors
Distinguished in Lung Metastases
Dr. Fernando A. Keller
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Distinguished in Lung Metastases
Dr. Fernando A. Keller
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Pulmonary Specialist Of Boynton Beach

2623 S Seacrest Blvd, Suite 214, 
Boynton Beach, FL 
 (34.4 miles away)
561-731-2269
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Fernando Keller is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Boynton Beach, Florida. Dr. Keller has been practicing medicine for over 46 years and is rated as a Distinguished provider by MediFind in the treatment of Lung Metastases. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Asthma in Children, Asthma, and Endoscopy. Dr. Keller is currently accepting new patients.

Distinguished in Lung Metastases
Dr. Barry L. Davis
Pulmonary Medicine
Distinguished in Lung Metastases
Dr. Barry L. Davis
Pulmonary Medicine

Pulmonary And Sleep Associates Of South Florida PA

951 Nw 13th St, Suite 2a, 
Boca Raton, FL 
 (25.1 miles away)
561-939-0200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Barry Davis is a Pulmonary Medicine provider in Boca Raton, Florida. Dr. Davis is rated as a Distinguished provider by MediFind in the treatment of Lung Metastases. His top areas of expertise are Bronchiectasis, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Pneumonia. Dr. Davis is currently accepting new patients.

Distinguished in Lung Metastases
Dr. Stuart J. Bernstein
Pulmonary Medicine
Distinguished in Lung Metastases
Dr. Stuart J. Bernstein
Pulmonary Medicine
21110 Biscayne Blvd, Suite 405, 
Aventura, FL 
 (15.7 miles away)
305-937-4400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stuart Bernstein is a Pulmonary Medicine provider in Aventura, Florida. Dr. Bernstein is rated as a Distinguished provider by MediFind in the treatment of Lung Metastases. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, Gastrostomy, and Endoscopy. Dr. Bernstein is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehta's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile